Growing threat to Eylea outlined at 2023 ARVO meeting

26 April 2023

Post-marketing research into Vabysmo (faricimab) shows superior performance to aflibercept in wet age-related macular degeneration (nAMD).

The findings are detailed in research presented by developer Roche (ROG: SIX), at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).

The post-hoc analysis of pooled data from the head-to-head dosing period (weeks zero to 12) of the Phase III TENAYA and LUCERNE studies in wet AMD showed that Vabysmo use led to greater and faster drying of retinal fluid.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK